Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Chief Medical Officer | December 06, 2019 | December 10, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date December 06, 2019 · Filed December 10, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.02 · Expires 2029-12-05 | Direct | 98,000 |
Reported balance
After 2019-12-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-06 · Grant · Acquired 98,000 · Balance 98,000 F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 06, 2019 Filed Dec 10, 2019 22:38 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 98,000 | $0.00 Strike: $14.02 | $0.00 |
DisclosureSEC source: 0001209191-19-059923 · doc4.xml · derivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 98,000 shares Expires 2029-12-05 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:29 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 46,202 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001209191-19-058549 · doc4.xml · derivative · entry 2 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,946 Underlying: Common Stock · 46,202 shares Expires 2025-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and immediately exercisable. F2 · balance_after: In addition to the remaining options to purchase 4,946 shares of common stock as set forth in Table II, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 173,000 shares of common stock, which options vest according to their terms, and (ii) 68,579 shares of common stock held directly. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:29 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 46,202 | $6.93 | $320,179.86 |
DisclosureSEC source: 0001209191-19-058549 · doc4.xml · nonDerivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 21:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,060 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-19-034870 · doc4.xml · derivative · entry 5 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,060 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F6 · balance_after: The Reporting Person also holds (i) additional options to purchase up to an aggregate of 224,148 shares of common stock, which options vest according to their terms, and (ii) 22,377 shares of common stock held directly. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 21:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,003 | $74.50 | $149,219.09 |
DisclosureSEC source: 0001209191-19-034870 · doc4.xml · nonDerivative · entry 4 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,377 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.085 to $74.78 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 21:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,048 | $73.43 | $150,383.82 |
DisclosureSEC source: 0001209191-19-034870 · doc4.xml · nonDerivative · entry 3 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,380 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.04 to $73.98 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 21:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 6,009 | $72.45 | $435,358.66 |
DisclosureSEC source: 0001209191-19-034870 · doc4.xml · nonDerivative · entry 2 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,428 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2019 Filed Jun 5, 2019 21:54 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 10,060 | $0.70 | $7,042.00 |
DisclosureSEC source: 0001209191-19-034870 · doc4.xml · nonDerivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2019 Filed Feb 11, 2019 22:28 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $68.89 | $0.00 |
DisclosureSEC source: 0001209191-19-009024 · doc4.xml · derivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 8, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 19,075 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001209191-19-003996 · doc4.xml · derivative · entry 5 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,148 Underlying: Common Stock · 19,075 shares Expires 2025-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F6 · balance_after: In addition to the remaining options to purchase 51,148 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 148,060 shares of common stock, which options vest according to their terms, and (ii) 22,377 shares of common stock held directly. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 14,894 | $70.04 | $1,043,195.12 |
DisclosureSEC source: 0001209191-19-003996 · doc4.xml · nonDerivative · entry 4 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,377 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.63 to $70.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 4,181 | $69.29 | $289,686.44 |
DisclosureSEC source: 0001209191-19-003996 · doc4.xml · nonDerivative · entry 3 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,271 F2 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.63 to $69.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 19,075 | $6.93 | $132,189.75 |
DisclosureSEC source: 0001209191-19-003996 · doc4.xml · nonDerivative · entry 2 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 26, 2018 Filed Jan 17, 2019 00:09 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GiftCommon Stock | 122,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-003996 · doc4.xml · nonDerivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,377 F1 · shares: Represents the number of shares of Issuer's common stock that were donated as a charitable contribution. The reporting person does not exercise voting or dispositive powers, directly or indirectly, over the donated shares following this transfer. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 02:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0001209191-18-063384 · doc4.xml · derivative · entry 8 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,223 Underlying: Common Stock · 22,000 shares Expires 2025-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F7 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. F8 · balance_after: In addition to the remaining options to purchase 80,283 shares of common stock as set forth in Table II, the Reporting Person also holds (i) 144,877 shares of common stock held directly; and (ii) additional options to purchase up to an aggregate of 138,000 shares of common stock, which options vest according to their terms. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 02:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,048 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-18-063384 · doc4.xml · derivative · entry 7 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,060 Underlying: Common Stock · 8,048 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 02:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 6,741 | $68.47 | $461,577.84 |
DisclosureSEC source: 0001209191-18-063384 · doc4.xml · nonDerivative · entry 6 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,877 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.05 to $68.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 02:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 8,002 | $67.57 | $540,683.94 |
DisclosureSEC source: 0001209191-18-063384 · doc4.xml · nonDerivative · entry 5 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,618 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.02 to $68.01 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 02:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,185 | $66.38 | $211,416.16 |
DisclosureSEC source: 0001209191-18-063384 · doc4.xml · nonDerivative · entry 4 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,620 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.00 to $66.92 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 02:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 12,120 | $65.36 | $792,177.74 |
DisclosureSEC source: 0001209191-18-063384 · doc4.xml · nonDerivative · entry 3 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,805 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.99 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 02:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 22,000 | $6.93 | $152,460.00 |
DisclosureSEC source: 0001209191-18-063384 · doc4.xml · nonDerivative · entry 2 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 02:48 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 8,048 | $0.70 | $5,633.60 |
DisclosureSEC source: 0001209191-18-063384 · doc4.xml · nonDerivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,925 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 23:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 142,857 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001209191-18-050362 · doc4.xml · derivative · entry 2 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,108 Underlying: Common Stock · 142,857 shares Expires 2024-10-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 23:06 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 142,857 | $0.70 | $99,999.90 |
DisclosureSEC source: 0001209191-18-050362 · doc4.xml · nonDerivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2018 Filed Jan 30, 2018 21:13 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $106.84 | $0.00 |
DisclosureSEC source: 0001209191-18-005997 · doc4.xml · derivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2028-01-25 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on January 26, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:42 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $24.60 | $0.00 |
DisclosureSEC source: 0001209191-17-015444 · doc4.xml · derivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 24, 2018, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:47 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionSeries D Preferred Stock · Derivative | 2,020 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006403 · doc4.xml · derivative · entry 2 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,020 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.exercise_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. F1 · derivative.expiration_date: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
| January 31, 2017 Filed Jan 31, 2017 21:47 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | ConversionCommon Stock | 2,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-006403 · doc4.xml · nonDerivative · entry 1 Londei Marco · CIK 0001654500 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,020 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: In connection with the consummation of the Issuer's initial public offering on January 31, 2017, each share of Series D Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.